Treatment satisfaction with siponimod in patients with advancing relapsing multiple sclerosis: Interim results of the EXCHANGE study

被引：0

作者：

Cohan, S. L. ^{[1
,2
]}

Fox, R. J. ^{[3
]}

Mao-Draayer, Y. ^{[4
]}

Bar-Or, A. ^{[5
,6
]}

Cox, G. Mavrikis ^{[7
]}

Meng, X. ^{[7
]}

Cruz, L-A ^{[7
]}

Weinstock-Guttman, B. ^{[8
]}

机构：

[1] Providence Hlth & Serv, Providence Brain & Spine Inst, Portland, OR USA

[2] Providence Hlth & Serv, Providence Multiple Sclerosis Ctr, Portland, OR USA

[3] Cleveland Clin, Neurol Inst, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA

[4] Univ Michigan, Multiple Sclerosis Ctr, Autoimmun Ctr Excellence, Ann Arbor, MI 48109 USA

[5] Univ Penn, Perelman Sch Med, Ctr Neuroinflammat & Expt Therapeut, Philadelphia, PA 19104 USA

[6] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA

[7] Novartis Pharmaceut, E Hanover, NJ USA

[8] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EP1145

引用

页码：901 / 902

页数：2

共 50 条

[41] Effects of siponimod on MRI outcomes in patients with secondary progressive multiple sclerosis: results of the phase 3 EXPAND study
Fox, R.
Arnold, D. L.
Bar-Or, A.
Cree, B.
Giovannoni, G.
Gold, R.
Vermersch, P.
Pohlmann, H.
Sidorenko, T.
Wolf, C.
Tomic, D.
Dahlke, F.
Kappos, L.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 34 - 35
[42] Five-year study of adherence to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results
Ramo, C.
Arroyo, E.
Sanchez-Solino, O.
JOURNAL OF NEUROLOGY, 2009, 256 : S125 - S125
[43] Efficacy and treatment satisfaction after switching therapy in patients with relapsing-remitting multiple sclerosis: the multicentre, observational SURFINIA study
Mantegazza, R.
Ulivelli, M.
Cottone, S.
Clerici, V. Torri
Ferro, M. T.
De Pascalis, D.
Veneziano, A.
Cuomo, D.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 955 - 956
[44] Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy
Filippi, Massimo
Ferre, Laura
Zanetta, Chiara
Rizzi, Caterina
Pessina, Gabriella
Assogna, Francesco
Rocca, Maria A.
FRONTIERS IN NEUROLOGY, 2024, 15
[45] Impact of Siponimod on Cognition in Patients With Secondary Progressive Multiple Sclerosis: Results From Phase 3 EXPAND Study
Benedict, Ralph H. B.
Cree, Bruce
Tomic, Davorka
Fox, Robert
Giovannoni, Gavin
Bar-Or, Amit
Gold, Ralf
Vermersch, Patrick
Pohlmann, Harald
Karlsson, Goril
Dahlke, Frank
Kappos, Ludwig
NEUROLOGY, 2018, 90
[46] The real-world safety and effectiveness of ocrelizumab in patients with relapsing multiple sclerosis - a confidence study interim analysis
Weber, M.
Buttmann, M.
Meuth, S.
Dirks, P.
Eggebrecht, J.
Hieke-Schulz, S.
Leemhuis, J.
Ziemssen, T.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 387 - 388
[47] Sustained Efficacy of Ofatumumab in Relapsing Multiple Sclerosis Patients: Results from Extended Treatment in the Phase 2 APOLITOS Study
Saida, Takahiko
Nakahara, Jin
Sazonov, Denis V.
Kurosawa, Takayoshi
Tsumiyama, Isao
Willi, Roman
Zalesak, Martin
Pingili, Ratnakar
Haring, Dieter A.
Ramanathan, Krishnan
Su, Wendy
Kira, Jun-ichi
NEUROLOGY, 2021, 96 (15)
[48] Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results
Cohen, Jeffrey A.
Tenenbaum, Nadia
Bhatt, Alit
Zhang, Ying
Kappos, Ludwig
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2019, 12
[49] Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results
Arroyo, E.
Grau, C.
Ramo, C.
Parra, J.
Sanchez-Solino, O.
NEUROLOGIA, 2010, 25 (07): : 435 - 442
[50] Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis
Singer, B.
Ross, A. P.
Tobias, K.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (08) : 887 - 895

← 1 2 3 4 5 →